Immunologic Factor – Page 25

AbbVie and Simcere Zaiming Collaborate on Novel Trispecific Antibody for Multiple Myeloma Treatment

8 months ago talkbio0Tagged AbbVie, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CD3 Antigens, GPRC5D, GPRC5D gene, Multiple Myeloma, Simcere, T-Lymphocyte, Trispecific Antibody, Zaiming

AbbVie, Simcere Zaiming, multiple myeloma, trispecific antibody, SIM0500, T-cell engager, GPRC5D, BCMA, CD3

Eli Lilly and Mediar Therapeutics Collaborate on Novel IPF Treatment with $780M+ Deal

8 months ago talkbio0Tagged Antibodies, CCN4 gene, Clinical Trials, Eli, Eli Lilly, Fibrosis, Idiopathic Pulmonary Fibrosis, licensing agreement, MTX-463

Eli Lilly, Mediar Therapeutics, Idiopathic Pulmonary Fibrosis (IPF), MTX-463, WISP1 antibody, fibrosis treatment, licensing agreement, clinical trials.

Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

8 months ago talkbio0Tagged BCG Vaccine, BCG-Naïve, Combined Modality Therapy, Event-Free Survival, Inhibitor, Invasive, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, PDCD1 gene, Pfizer, Sasanlimab, subcutaneous

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG

Pfizer’s Sasanlimab Shows Promising Results in Phase 3 Trial for High-Risk Non-Muscle Invasive Bladder Cancer

8 months ago talkbio0Tagged BCG Vaccine, Blocker, Carcinoma of urinary bladder, invasive, Keytruda, Malignant neoplasm of urinary bladder, Non-Muscle, PDCD1 gene, Pfizer, Phase 3 trial, Sasanlimab

Pfizer, Sasanlimab, PD-1 Blocker, Bladder Cancer, Phase 3 Trial, Non-Muscle Invasive Bladder Cancer, BCG, Keytruda

Marea Therapeutics Announces Breakthrough Phase II Results for MAR001, a Novel Monoclonal Antibody Targeting Remnant Cholesterol

8 months ago talkbio0Tagged ANGPTL4, Cardiovascular Diseases, cholesterol, MAR001, Marea Therapeutics, Monoclonal Antibodies, Phase 2 Clinical Trials, Remnant

Marea Therapeutics, MAR001, Remnant Cholesterol, Monoclonal Antibody, Cardiovascular Disease, ANGPTL4, Phase II Clinical Trial

IGM Biosciences Halts Autoimmune Projects Amid Layoffs Following Disappointing Trial Data

8 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, bispecific antibody T cell, engagers, IGM-2644, Immunoglobulin M, imvotamab, Industry

IGM Biosciences, layoffs, autoimmune diseases, bispecific antibody T cell engagers, imvotamab, IGM-2644, biotech industry

FDA Mandates Guillain-Barré Syndrome Warning for Pfizer and GSK RSV Vaccines

8 months ago talkbio0Tagged Abrysvo, Arexvy, Cautionary Warning, Guillain-Barré syndrome, Pfizer, Respiratory syncytial virus, SmithKline Beecham, United States Food and Drug Administration, Vaccines

RSV vaccines, Guillain-Barré syndrome, FDA warning, Pfizer, GSK, Abrysvo, Arexvy

Pfizer and PostEra Expand AI-Driven Drug Discovery Partnership to Include Antibody-Drug Conjugates (ADCs)

8 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Aortic Valve Insufficiency, Chemistry, Pharmaceutical, Drug Discovery, Immunostimulating conjugate (antigen), Laboratory, Pfizer, Pfizer/, PostEra, Proton Platform, Small Molecule

AI-driven drug discovery, Antibody-Drug Conjugates (ADCs), Pfizer, PostEra, AI Lab, Proton platform, small molecule therapeutics, medicinal chemistry.